Abstract
The pharmacokinetics of chloramphenicol (CAP) and total chloramphenicol succinate (CAPS) were studied in eight hospitalized adult patients with normal renal and hepatic function receiving intravenous chloramphenicol sodium succinate therapy. The steady-state peak concentrations of CAP (8.4–26.0 μg/ml) occurred at an average of 18.0 min (range 5.4–40.2) after cessation of the chloramphenicol sodium succinate infusion. Unhydrolyzed CAPS prodrug, representing 26.0±7.0% of the dose, was recovered unchanged in the urine indicating that the bioavailability of CAP from a dose of intravenous chloramphenicol succinate is not complete. A pharmacokinetic model was developed for simultaneous fitting of CAP and CAPS plasma concentration data. Pharmacokinetic parameters determined by simultaneous fitting were: V, 0.81±0.18 liters/kg; t1/2, 3.20 ±1.02 hr; CLB, 3.21±1.27 ml/min/kg for chloramphenicol; and V, 0.38±0.13 liters/kg; t1/2, 0.57±0.12hr; CLB, 7.72±1.87 ml/min/kg for total chloramphenicol succinate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
D. A. Brent, P. Chandrasurin, A. Ragonzeos, B. S. Hurlbert, and J. T. Burke. Rearrangement of chloramphenicol-3-monosuccinate.J. Pharm. Sci. 69:906–908 (1980).
J. T. Burke, W. A. Wargin, and M. R. Blum. High-pressure liquid Chromatographic assay for chloramphenicol, chloramphenicol-3-monosuccinate, and chloramphenicol-1-monosuccinate.J. Pharm. Sci. 69:909–912 (1980).
A. J. Glazko, W. A. Dill, and M. C. Rebstock. Biochemical studies on chloramphenicol III. Isolation and identification of metabolic products in urine.J. Biol. Chem. 183:679–691 (1950).
A. J. Glazko. Identification of chloramphenicol metabolites and some factors affecting metabolic disposition.Antimicrob. Agents Chemother. 6:655–665 (1966).
O. Schück, K. Cholínský, O. Smahel, and J. Grafnetterová. Renal excretion and intestinal absorption of d-chloramphenicol.Antibiot. Med. Clin. Ther. 6:98–102 (1959).
G. Betzien and W. Vömel. Pharmacokinetic studies on chloramphenicol. InProgess in Antimicrobial and Anticancer Chemotherapy, Vol. II, Proceedings of the 6th International Congress of Chemotherapy, 1970. University Park Press, Baltimore, pp. 914–924, 1970.
G. Betzien, and V. Vömel. Zur relativmessung der enteraten resorption von arzneimitteln mit hilfe pharmakokineticsh festgelegter serumspiegelkurven am beispiel des chloramphenicols.Arzneim. Forsch. 16:1008–1018 (1966).
C. M. Kunin, A. J. Glazko, and M. Finland. Persistance of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis.J. Clin. Invest. 38:1498–1508(1959).
F. Azzollini, A. Gazzaniga, E. Lodola, R. Natangelo. Elimination of chloramphenicol in subjects with cirrhosis of the liver.Int. J. Clin. Pharmacol. 6:130–134 (1972).
R. L. Slaughter, J. A. Pieper, F. B. Cerra, B. Brodsky, and J. R. Koup. Chloramphenicol sodium succinate kinetics in critically ill patients.Clin. Pharmacol. Ther. 28:69–77 (1980).
R. E. Kauffman, J. N. Miceli, L. Strebel, J. A. Buckley, A. K. Done, and A. S. Dajani. Pharmacokinetics of Chloramphenicol and chloramphenicol succinate in infants and children.J. Pediatr. 98:315–320 (1981).
M. C. Nahata and D. A. Powell. Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate.Clin. Pharmacol. Ther. 30:368–372 (1981).
A. J. Glazko, W. A. Dill, A. W. Kinkel, J. R. Goulet, W. J. Holloway, and R. A. Buchanan. Absorption and excretion of parenteral doses of chloramphenicol sodium succinate in comparison with peroral doses of chloramphenicol.Clin. Pharmacol. Ther. 21:104 (1977).
C. M. Metzler, G. K. Elfring, and A. J. McEwen. A package of computer programs for pharmacokinetic modeling.Biometrics 3:562 (1974).
M. Gibaldi and D. Perrier.Pharmacokinetics. Marcel Dekker, New York, 1975, p. 55.
R. E. Kauffman, M. C. Thirumoorthi, J. A. Buckley, M. K. Aravind, and A. S. Dajani. Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children.J. Pediatr. 99:963–967 (1981).
A. J. Glazko, L. M. Wolf, W. A. Dill, and A. C. Bratton, Jr. Biochemical studies on chloramphenicol (chloromycetin) II. Tissue distribution and excretion studies.J. Pharmacol. Exp. Ther. 96:445–459 (1949).
O. Schück, V. Prát, J. Grafnetterová, I. David, E. Kotanová, and V. Reitschlagerová. Excretion of chloramphenicol and its metabolites by the chronically diseased kidney (with respect to the theory of adaptive nephrons).Int. J. Clin. Pharmacol. 10:33–43 (1974).
J. R. Koup, A. H. Lau, B. Brodosky, and R. L. Slaughter. Relationship between serum and saliva chloramphenical concentrations.Antimicrob. Agents Chemother. 15:658–661 (1979).
A. A. Lindberg, L. H. Nilsson, H. Bucht, and L. O. Kallings. Concentration of chloramphenicol in the urine and blood in relation to renal function.Brit. Med. J. 2:724–728 (1966).
Author information
Authors and Affiliations
Additional information
Supported in part by Faculty Research Council Grant VF648 from the University of North Carolina.
Rights and permissions
About this article
Cite this article
Burke, J.T., Wargin, W.A., Sherertz, R.J. et al. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. Journal of Pharmacokinetics and Biopharmaceutics 10, 601–614 (1982). https://doi.org/10.1007/BF01062543
Received:
Revised:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF01062543